Analytical instrument maker Waters beats Q3 sales estimates, raises guidance

Waters

04/11/2025 11:13

Overview

Waters Q3 sales grew 8% yr/yr to $800 mln, beating analyst expectations

Adjusted EPS for Q3 rose 16% to $3.40, exceeding analyst expectations

Company raises full-year 2025 sales and non-GAAP EPS guidance

Outlook

Waters raises full-year 2025 constant currency sales growth guidance to 6.7%-7.3%

Waters raises full-year 2025 non-GAAP EPS guidance to $13.05-$13.15

Waters expects Q4 2025 constant currency sales growth of 5.0%-7.0%

Result Drivers

PHARMA GROWTH - Pharma sector grew 11% in constant currency, driven by broad-based growth across all regions, including double-digit growth in the Americas

INSTRUMENTS GROWTH - Instruments segment grew 6% in constant currency, led by high single-digit growth in LC & MS

RECURRING REVENUE - Recurring revenue grew 9% in constant currency; chemistry grew double digits, with strong uptake of new bioseparations products

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$800 mln
$781.01 mln (14 Analysts)
Q3 Adjusted EPS
Beat
$3.40
$3.20 (14 Analysts)
Q3 EPS
$2.50


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Waters Corp is $355.00, about 2.7% above its November 3 closing price of $345.59

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nPnbTQxbTa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)